AAV Manufacturing
ProBio Launches GMP AAV Manufacturing Services at Hopewell Facility to Advance Gene Therapy Development and Manufacturing
ProBio Inc
PR-08-25-NI-01Aug 11, 2025
Viral Vectors
De-Risking Cell and Gene Therapies with Innovative Solutions: A Review for Leveraging a Proven Workhorse Technology in New Ways
Farzin Farzaneh, Ph.D.; Nicholas Ostrout, Ph.D.; Glenda Dickson, Ph.D.; David Darling, Ph.D.
ViroCell Biologics
PAO-06-25-CL-12Jul 31, 2025
Viral Vector Manufacturing
Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control
Chris Berger; Kilian Witzel
Avid Bioservices
PAO-02-23-CL-03Mar 14, 2023
AAV Capsid Engineering
Expanding Patient Access to Gene Therapies through AAV Capsid Engineering
Damien Marsic, Ph.D.
Porton Advanced Solutions
PAO-01-23-CL-02-155Feb 06, 2023
Viral Vector Manufacturing
Optimizing Transient Transfection for Viral Vector Production
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.
Pharma's Almanac
PAO-11-022-NI-09Nov 15, 2022
Viral Vectors
Risk-Based Optimization of Viral Vector Processes Adds Real Value
Elie Hanania, Ph.D.; Tatiana Mello, M.S.
Avid Bioservices
PAO-09-022-CL-05Oct 25, 2022
Cell and Gene Therapy
State of the Cell and Gene Therapy Market
James Grote
Nice Insight
PAO-10-022-NI-01Oct 11, 2022
Column: M&A
Who's Left to Acquire in CDMO Biomanufacturing? A Select Few.
Nigel Walker
Nice Insight
PAO-06-022--NI-12Jun 24, 2022
Viral Vector Manufacturing
Avid Bioservices, Inc. and CRB Highlight Efforts that Enabled Opening of First Phase of New Viral Vector Facility in California in Only Eight Months
Avid Bioservices
PR-M06-22-05Jun 16, 2022
Viral Vector Manufacturing
Approaching Viral Vector Manufacturing With an Emphasis on Quality and Design
Chris Berger; Atef Khezri
Avid Bioservices
PAO-05-022-CL-02May 10, 2022
GMP Certification
GMP Certification for Exothera Further Extends its Viral Vector Manufacturing Capacity
Exothera
PR-M03-22-10Mar 23, 2022
Viral Vector Manufacturing
Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing
Andrew Moreo; Lenore Giannunzio
Andelyn Biosciences
PAO-02-022-CL-01Mar 12, 2022
Viral Vectors
Smart Scale-Up: Expanding Viral Vectors With Microcarrier Bead Technology
Heidi Trusheim, Ph.D.
IDT Biologika
PAO-02-022-CL-09Mar 12, 2022
2021 Roundup: The Year of Cell and Gene Therapy
David Alvaro, Ph.D.
Pharma's Almanac
PA734Dec 20, 2021
Viral Vaccines
Viral Vectors, Vaccines — A New Era Of Collaborative Design
Andreas Neubert, Ph.D.
IDT Biologika
PAO-10-21-CL-17Nov 08, 2021
Cell and Gene Therapy
Coping with a Talent Shortage and Talent War in Cell and Gene Therapy
Cyrill Kellerhals; Sarah O'Reilly
Andelyn Biosciences
PAO-10-21-CL-12Oct 26, 2021
Gene Therapy
A Customer-Centric Approach to Cell and Gene Therapy Manufacturing
Drew Brennan
Avid Bioservices
PAO-10-21-CL-06Oct 13, 2021
Viral Vectors
Navigating Analytical Requirements for GMP Viral Vectors
Will Fountain
Andelyn Biosciences
PAO-10-21-CL-02Oct 08, 2021
Gene Therapy
Building a Bridge of Equivalence to Facilitate and Implement Rapid Process Changes in Gene Therapy Manufacturing
Wade Macedone; Jonathan Rush; Phillip Vermilion; Samir Acharya, Ph.D.
Andelyn Biosciences
PAO-10-21-CL-01Oct 07, 2021
Gene Therapy
Pandemic Playbook for Gene Therapy Manufacturing
Ratish Krishnan; David Loong, Ph.D.; Nargisse El-Hajjami, Ph.D.
MilliporeSigma
PAO-09-21-CL-14Sep 29, 2021